Peer Review History

Original SubmissionJanuary 7, 2025
Decision Letter - Yusuf Ahmed Haggag, Editor

PONE-D-24-58989Decoding Oncogenic Secrets of Regulator of Chromosome Condensation 1: A Breakthrough Mechanistic Evidence from Breast and Lung Cancer ModelsPLOS ONE

Dear Dr. Hatahet,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 05 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Yusuf Ahmed Haggag, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.

3. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Reviwer feedback:

"Decoding Oncogenic Secrets of RCC1: A Breakthrough Mechanistic Evidence from Breast and Lung Cancer Models" addresses the role of the Regulator of Chromosome Condensation 1 (RCC1) in cancer progression. This study investigates RCC1's role in the regulation of cell viability, apoptosis, and metastatic behavior in breast and lung cancer models. This identified RCC1 as a potentially actionable target for the treatment of aggressive cancers. Well-written and easy to read, this is a robust study with well-described experiments and a sound conceptual basis addressing an unmet clinical need.

However, I have several comments listed below for the authors’ consideration that would improve and make the manuscript publishable:

Introduction

• The introduction provides a clear description of the research question and places RCC1 within the broader context of cancer biology. However, some areas lack clarity, such as the link between the cellular functions of RCC1 and its oncogenic potential. Adding a sentence to RCC1’s functions in non-cancerous cells would facilitate completeness.

Methods

• The experimental procedures are described in sufficient detail for reproducibility to a large extent. However:

RNA microarray analysis is underdescribed; specifically, normalization methods and statistical thresholds are missing.

o Discuss the potential for off-target effects of shRNAs and how they are controlled.

Results

The data are presented clearly, with logical flow from one experiment to the next. Figures 1–5 are generally appropriate; however, Figure 1E needs to be enlarged, showing larger data points and displaying the exact p-values.

Discussion

Places the findings well but overstates their clinical applicability. A paragraph on the possible side effects targeting RCC1,

1. Lacking Mechanistic Details: Further investigation of how RCC1 interacts with downstream signaling pathways, such as AKT and Bcl2.

2. Lack of Context of RCC1 in Non-Cancer Models: Such a broader context would considerably raise the level of novelty in the present study.

1. Kaplan-Meier survival curves and statistical models require further explanation.

Recommendation:

The manuscript contributes improtant findings but needs to be revised for methodological gaps, refinement in data presentation, and balancing while discussing the findings.

Reviewer #2: The study is rigorously planned and executed. Data is clear and the results are clearly statistically significant. The outcome of the study is of great potential for the treatment of cancer specifically lung and breast cell line models. The paper is easy to follow and understand. The experiments have been conducted in standard methodologies and the conclusion matches with the presented results. No issues to comment on really. Well done!

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Mohammad Isreb

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Authors’ Point by Point Response to Reviewers’ Comments

The authors extend their gratitude to the esteemed Editor and both the Reviewers for their valuable time, patience, and dedication in reviewing our manuscript. We sincerely appreciate the insightful feedback provided, which has significantly enhanced the scientific rigor and relevance of our work. We are particularly thankful to reviewers for their constructive comments and suggestions, which have guided us in refining various aspects of the manuscript. Each of their points has been meticulously addressed in the revised version of manuscript (changes highlighted in red colored font), aimed at strengthening the scientific merit and clarity of our findings. We have also revised figures as per the suggestions given by the reviewers. The manuscript has been revised to address methodological gaps, refine data presentation, and provide a more balanced discussion of the findings. Thank you once again for your invaluable contribution and patience throughout this process.

REVIEWER 1

Reviewer 1; Comment 1: Decoding Oncogenic Secrets of RCC1: A Breakthrough Mechanistic Evidence from Breast and Lung Cancer Models" addresses the role of the Regulator of Chromosome Condensation 1 (RCC1) in cancer progression. This study investigates RCC1's role in the regulation of cell viability, apoptosis, and metastatic behavior in breast and lung cancer models. This identified RCC1 as a potentially actionable target for the treatment of aggressive cancers. Well-written and easy to read, this is a robust study with well-described experiments and a sound conceptual basis addressing an unmet clinical need.

The introduction provides a clear description of the research question and places RCC1 within the broader context of cancer biology. However, some areas lack clarity, such as the link between the cellular functions of RCC1 and its oncogenic potential. Adding a sentence to RCC1’s functions in non-cancerous cells would facilitate completeness.

Response: We sincerely appreciate the reviewer’s thoughtful and encouraging feedback. It is gratifying to know that our study was found to be well-written, conceptually sound, and addressing an unmet clinical need. We are especially grateful for the recognition of our efforts in investigating RCC1’s role in cancer progression and its potential as a therapeutic target. Your positive remarks motivate us to continue our research in this critical area. Thank you for your valuable time and insightful evaluation.

Thank you for this valuable suggestion. We have now included a sentence elaborating on RCC1’s role in non-cancerous cells, emphasizing its physiological functions in cell cycle regulation and chromatin dynamics. This addition provides a clearer foundation for understanding its oncogenic potential.

Reviewer 1; Comment 2: The experimental procedures are described in sufficient detail for reproducibility to a large extent. However, RNA microarray analysis is under described; specifically, normalization methods and statistical thresholds are missing.

Response: Thank you for highlighting this. We have now detailed the normalization methods and statistical thresholds used in the RNA microarray analysis to ensure clarity and reproducibility.

Reviewer 1; Comment 3: Discuss the potential for off-target effects of shRNAs and how they are controlled.

Response: We appreciate your suggestion. We have now included a section discussing the potential off-target effects of shRNAs. Additionally, we have described the validation steps taken, such as using multiple shRNA constructs and performing qPCR validation, to ensure specificity.

Reviewer 1; Comment 4: Figures 1–5 are generally appropriate; however, Figure 1E needs to be enlarged, showing larger data points and displaying the exact p-values.

Response: Thank you for this suggestion. We have now enlarged Figure 1E, increased the data point size for better visibility, and included exact p-values in the text to enhance clarity.

Reviewer 1; Comment 5: Places the findings well but overstates their clinical applicability. A paragraph on the possible side effects targeting RCC1 is needed.

Response: We acknowledge this concern and have now included a paragraph discussing the potential side effects and challenges of targeting RCC1 therapeutically. This revision ensures a balanced discussion of clinical implications.

Reviewer 1; Comment 6: Lacking mechanistic details: Further investigation of how RCC1 interacts with downstream signaling pathways, such as AKT and Bcl2.

Response: Thank you for the recommendation. We have expanded our discussion to include mechanistic insights into RCC1’s interaction with the AKT and Bcl2 pathways.

Reviewer 1; Comment 7: Lack of context of RCC1 in non-cancer models: Such a broader context would considerably raise the level of novelty in the present study.

Response: We appreciate this valuable suggestion. We have now included a discussion on RCC1’s function in non-cancerous models, which enhances the novelty and relevance of our findings.

Reviewer 1; Comment 8: Kaplan-Meier survival curves and statistical models require further explanation.

Response: Thank you for your suggestion. We have now provided additional details on the statistical models used for Kaplan-Meier survival curves, including the specific tests applied and how significance was determined.

REVIEWER 2

Reviewer 2; Comment 1: The study is rigorously planned and executed. Data is clear and the results are statistically significant. The outcome of the study is of great potential for the treatment of cancer, specifically lung and breast cancer models. The paper is easy to follow and understand. The experiments have been conducted using standard methodologies, and the conclusion matches the presented results. No issues to comment on really. Well done!

Response: We sincerely appreciate the reviewer’s positive and encouraging feedback. It is highly rewarding to know that our study was found to be rigorously planned and executed, with clear data and statistically significant results. We are grateful for your recognition of the study’s potential impact on cancer treatment and your acknowledgment of the clarity and methodological rigor of our work. Your kind words motivate us to continue our research in this important field. Thank you for your time and valuable assessment.

***

Attachments
Attachment
Submitted filename: Rebuttal letter.pdf
Decision Letter - Yusuf Ahmed Haggag, Editor

Decoding Oncogenic Secrets of Regulator of Chromosome Condensation 1: A Breakthrough Mechanistic Evidence from Breast and Lung Cancer Models

PONE-D-24-58989R1

Dear Dr. Hatahet,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yusuf Ahmed Haggag, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Formally Accepted
Acceptance Letter - Yusuf Ahmed Haggag, Editor

PONE-D-24-58989R1

PLOS ONE

Dear Dr. Hatahet,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yusuf Ahmed Haggag

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .